A Phase 4 interventional study of andexanet alfa and Usual Care in Acute Intracranial Hemorrhage, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 142 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Thrombosis with a site in Germany — 3 open to participants now, 4 under way, none of them phase 3. Thrombosis · Germany.
Among the 54 studies in Thrombosis with a site in Germany, this one is the 11th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2019, is one of 5 in phase 4, and was the 41st registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →3 of the 54 studies in Thrombosis with a site in Germany are open now. Recruiting first, the newest first:
LeMaitre Vascular · Sites in Germany, Switzerland
Ages 18+
Sciema UG · Sites in Germany, United States
Ages 18–80 · Healthy volunteers
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany, Austria
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 5
First in 2001; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 530 is above the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 229 across the 33 interventional studies, 300 across the 21 observational. Of the 41 that completed or were terminated, 22 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
AstraZeneca has 3 studies filed under Thrombosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Thrombosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05386342LeMaitre VascularA PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies in Thrombosis with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant
This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet alfa compared to usual care in patients presenting with acute intracranial hemorrhage within 6 hours of symptom onset to baseline scan and within 15 hours of taking an oral factor Xa inhibitor. The study will use a prospective, randomized, open label (PROBE) design. The primary efficacy outcome will be adjudicated by a blinded Endpoint Adjudication Committee. To support the adjudication of hemostatic efficacy, a blinded Imaging Core Laboratory will review all available scans. Between 900 and 1200 patients are planned to be enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Written . Either the patient or his or her medical proxy (or legally authorized representative if permissible by local or regional laws and regulations) has been adequately informed of the nature and risks of the study and has given written informed consent prior to Screening.
Treatment with an oral FXa inhibitor (apixaban [last dose 2.5 mg or greater], rivaroxaban [last dose 10 mg or greater], or edoxaban [last dose 30 mg or greater]):
Exclusion Criteria
If a patient meets any of the following criteria, he or she is not eligible to participate in this trial:
Recent history (within 2 weeks) of a diagnosed TE or symptoms of the following:
○ Venous Thromboembolism (VTE: e.g., deep venous thrombosis, PE, cerebral venous thrombosis), myocardial infarction (MI), Disseminated Intravascular Coagulation (DIC), cerebral vascular accident, (TIA), acute coronary syndrome, or arterial systemic embolism.
Receipt of any of the following drugs or blood products within 7 days prior to consent:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive one of two dosing regimens of andexanet alfa based on which FXa inhibitor they received and the amount and timing of the most recent dose.
Drug: andexanet alfa
Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
Drug: Usual Care
Andexanet alfa is a recombinant version of human FXa
Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
Number of Participants Who Achieved Effective Hemostasis
Effective hemostasis was defined as a change from baseline in National Institutes of Health Stroke Scale (NIHSS) of + 6 or less at the 12 hour timepoint and ≤35% increase in haematoma volume compared to baseline on a repeat computed tomography (CT) or magnetic resonance imaging (MRI) scan at 12 hours and no rescue therapies administered between 3 hours and 12 hours after randomization (defined as excellent or good hemostasis). The NIHSS is a validated quantitative assessment tool to measure stroke-related neurological deficits and ranges from 0 (no neurological deficits) to a maximum of 42, indicative of a very severe level of impairment. Data presented is for the number of participants who achieved effective hemostasis (excellent or good hemostasis), as adjudicated by the independent Endpoint Adjudication Committee (IEAC).
Time frame: Baseline up to 12 hours
Percentage Change From Baseline to Nadir in Anti-FXa Activity
Anti-FXa activity was measured from plasma samples to assess the anticoagulant status of FXa inhibitors using a modified chromogenic assay performed at a Central Laboratory. Nadir was defined as the minimum anti-FXa activity post-randomization.
Time frame: Baseline up to 2 hours
| Milestone | Andexanet Alfa | Usual Care |
|---|---|---|
| Started | 263 | 267 |
| Received at least 1 dose of study drug | 262 | 265 |
| Completed | 180 | 193 |
| Not completed | 83 | 74 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Other than specified | 5 | 2 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Disease progression | 8 | 13 |
| Withdrew: Adverse event | 61 | 55 |
Effective hemostasis was defined as a change from baseline in National Institutes of Health Stroke Scale (NIHSS) of + 6 or less at the 12 hour timepoint and ≤35% increase in haematoma volume compared to baseline on a repeat computed tomography (CT) or magnetic resonance imaging (MRI) scan at 12 hours and no rescue therapies administered between 3 hours and 12 hours after randomization (defined as excellent or good hemostasis). The NIHSS is a validated quantitative assessment tool to measure stroke-related neurological deficits and ranges from 0 (no neurological deficits) to a maximum of 42, indicative of a very severe level of impairment. Data presented is for the number of participants who achieved effective hemostasis (excellent or good hemostasis), as adjudicated by the independent Endpoint Adjudication Committee (IEAC).
| Participants | Andexanet Alfa | Usual Care |
|---|---|---|
| Number of Participants Who Achieved Effective Hemostasis | 150 | 121 |
Anti-FXa activity was measured from plasma samples to assess the anticoagulant status of FXa inhibitors using a modified chromogenic assay performed at a Central Laboratory. Nadir was defined as the minimum anti-FXa activity post-randomization.
| Percent change | Andexanet Alfa | Usual Care |
|---|---|---|
| Percentage Change From Baseline to Nadir in Anti-FXa Activity | -94.41 (-99.1 to 1805.0) | -27.46 (-97.9 to 416.0) |
Collected over Up to approximately 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Andexanet Alfa | 75/263 (28.5%) | 120/262 (45.8%) | 198/262 (75.6%) |
| Usual Care | 70/267 (26.2%) | 96/265 (36.2%) | 200/265 (75.5%) |
| Event | Andexanet Alfa | Usual Care |
|---|---|---|
| PneumoniaInfections and infestations | 14/262 | 16/265 |
| Pneumonia aspirationInfections and infestations | 14/262 | 7/265 |
| Ischaemic strokeNervous system disorders | 13/262 | 2/265 |
| Haemorrhage intracranialNervous system disorders | 8/262 | 11/265 |
| Cerebral haemorrhageNervous system disorders | 7/262 | 11/265 |
| Myocardial infarctionCardiac disorders | 8/262 | 1/265 |
| HydrocephalusNervous system disorders | 7/262 | 4/265 |
| Neurological decompensationNervous system disorders | 2/262 | 7/265 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/262 | 7/265 |
| SepsisInfections and infestations | 6/262 | 2/265 |
| Event | Andexanet Alfa | Usual Care |
|---|---|---|
| Urinary tract infectionInfections and infestations | 54/262 | 44/265 |
| HypokalaemiaMetabolism and nutrition disorders | 40/262 | 28/265 |
| ConstipationGastrointestinal disorders | 39/262 | 25/265 |
| PneumoniaInfections and infestations | 28/262 | 25/265 |
| DeliriumPsychiatric disorders | 20/262 | 26/265 |
| HeadacheNervous system disorders | 24/262 | 19/265 |
| NauseaGastrointestinal disorders | 23/262 | 17/265 |
| PyrexiaGeneral disorders | 23/262 | 22/265 |
| Pneumonia aspirationInfections and infestations | 19/262 | 16/265 |
| HypertensionVascular disorders | 18/262 | 19/265 |
Measured in the Intent-to-Treat Population (ITT), Extended Population, which included all randomized participants according to the randomized treatment.
| Age, Continuous(years) | Andexanet Alfa | Usual Care | Total |
|---|---|---|---|
| Mean | 79.4 ± 8.51 | 78.7 ± 8.61 | 79.0 ± 8.56 |
| Sex: Female, Male(Participants) | Andexanet Alfa | Usual Care | Total |
|---|---|---|---|
| Female | 117 | 128 | 245 |
| Male | 146 | 139 | 285 |
| Ethnicity (NIH/OMB)(Participants) | Andexanet Alfa | Usual Care | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 13 | 28 |
| Not Hispanic or Latino | 227 | 237 | 464 |
| Unknown or Not Reported | 21 | 17 | 38 |
| Race (NIH/OMB)(Participants) | Andexanet Alfa | Usual Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 4 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 4 | 9 |
| White | 239 | 247 | 486 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 16 | 12 | 28 |
Showing the first 100 of 142 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in May 2023, 47 months.
Results were first posted in Jul 2024, 1 year 1 month after primary completion.
Of 34 phase 4 interventional studies under Thrombosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 63. This study's 47 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PRT064445
Alexion Pharmaceuticals, Inc. →